Toll Free: 1-888-928-9744
Published: Dec, 2016 | Pages:
73 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) - Pipeline Review, H2 2016', provides in depth analysis on Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) targeted pipeline therapeutics. The report provides comprehensive information on the Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note: *Certain sections in the report may be removed or altered based on the availability and relevance of data. *Updated report will be delivered in 48 hours of order confirmation. Scope - The report provides a snapshot of the global therapeutic landscape for Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) - The report reviews Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) targeted therapeutics and enlists all their major and minor projects - The report assesses Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential ands scope
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) Overview 7 Therapeutics Development 8 Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) - Products under Development by Stage of Development 8 Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) - Products under Development by Therapy Area 9 Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) - Products under Development by Indication 10 Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) - Pipeline Products Glance 12 Late Stage Products 12 Early Stage Products 13 Unknown Stage Products 14 Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) - Products under Development by Companies 15 Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) - Therapeutics Assessment 18 Assessment by Monotherapy/Combination Products 18 Assessment by Mechanism of Action 19 Assessment by Route of Administration 21 Assessment by Molecule Type 23 Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) - Companies Involved in Therapeutics Development 25 BioLingus AG 25 Celsion Corp 26 Johnson & Johnson 27 NeuClone Pty Ltd 28 Oncobiologics Inc 29 OncoSec Medical Inc 30 Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) - Drug Profiles 31 DNA IL-12 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 GEN-1 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 Monoclonal Antibody to Inhibit IL-23 for Crohn's Disease and Psoriasis - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 ustekinumab - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 ustekinumab biosimilar - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 ustekinumab biosimilar - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 ustekinumab biosimilar - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) - Dormant Projects 56 Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) - Featured News & Press Releases 58 Dec 16, 2016: Janssen Submits Application Seeking FDA Approval of STELARA (Ustekinumab) for the Treatment of Adolescents with Moderate to Severe Plaque Psoriasis 58 Dec 01, 2016: Stelara Now Available for Therapeutic Drug Monitoring from Miraca Life Sciences 58 Dec 01, 2016: Celsion Announces Positive DSMB Review of Phase 1b OVATION Study in Ovarian Cancer 59 Nov 17, 2016: OncoSec Announces Key Corporate Initiatives at Inaugural Investor & Analyst Day on November 17, 2016 59 Nov 16, 2016: Phase 3 Study Results Supporting U.S. Fda And European Commission Approvals Of Stelara In The Treatment Of Moderately To Severely Active Crohn's Disease Published In The New England Journal Of Medicine 60 Nov 11, 2016: European Commission Approves STELARA (ustekinumab) for Treatment of Adults with Moderately to Severely Active Crohn's Disease 62 Nov 11, 2016: OncoSec Presents Positive Interim Response Data at the Society for Immunotherapy of Cancer Annual Meeting 2016 63 Nov 10, 2016: Celsion Announces Continuing Positive Data from the OVATION Study - An Immunotherapy Study of Newly Diagnosed Stage III and IV Ovarian Cancer Patients 63 Nov 08, 2016: OncoSec Announces Positive Interim Response Data at the Society for Immunotherapy of Cancer Annual Meeting 2016 65 Nov 04, 2016: Celsion Announces Issuance of Two New U.S. Patents for its GEN-1 Immuno-Oncology Product 66 Nov 01, 2016: OncoSec to Present at Scientific and Investment Conferences and to Host Inaugural Investor and Analyst Day in November 66 Oct 18, 2016: OncoSec to Host Investor & Analyst Day on November 17, 2016 Spotlighting Industry-Leading Intratumoral Immunotherapy Pipeline and Next Generation Research and Device Development 67 Oct 13, 2016: OncoSec Announces Acceptance of Late Breaking Abstract at Upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting 2016 68 Sep 26, 2016: FDA Approves STELARA (Ustekinumab) for Treatment of Adults With Moderately to Severely Active Crohn's Disease 68 Sep 16, 2016: Janssen Receives CHMP Positive Opinion for STELARA (ustekinumab) Recommending Approval for the Treatment of Moderately to Severely Active Crohn's Disease in the European Union 70 Appendix 72 Methodology 72 Coverage 72 Secondary Research 72 Primary Research 72 Expert Panel Validation 72 Contact Us 72 Disclaimer 73
List of Tables Number of Products under Development for, H2 2016 8 Number of Products under Development by Therapy Area, H2 2016 9 Number of Products under Development by Indication, H2 2016 11 Comparative Analysis by Late Stage Development, H2 2016 12 Comparative Analysis by Early Stage Products, H2 2016 13 Comparative Analysis by Unknown Stage Development, H2 2016 14 Number of Products under Development by Companies, H2 2016 15 Products under Development by Companies, H2 2016 16 Products under Development by Companies, H2 2016 (Contd..1) 17 Assessment by Monotherapy/Combination Products, H2 2016 18 Number of Products by Stage and Mechanism of Action, H2 2016 20 Number of Products by Stage and Route of Administration, H2 2016 22 Number of Products by Stage and Molecule Type, H2 2016 24 Pipeline by BioLingus AG, H2 2016 25 Pipeline by Celsion Corp, H2 2016 26 Pipeline by Johnson & Johnson, H2 2016 27 Pipeline by NeuClone Pty Ltd, H2 2016 28 Pipeline by Oncobiologics Inc, H2 2016 29 Pipeline by OncoSec Medical Inc, H2 2016 30 Dormant Projects, H2 2016 56 Dormant Projects (Contd..1), H2 2016 57
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.